Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences (GILD) PT Lowered to $87 at Cantor Fitzgerald

February 12, 2019 7:14 AM EST

Cantor Fitzgerald analyst Alethia Young lowered the price target on Gilead Sciences (NASDAQ: GILD) to $87.00 (from $92.00) while maintaining a Overweight rating after speaking with management.

STELLAR3 is set to read out in 2Q, and Cantor Fitzgerald has increased caution after the F4... More

Gilead Sciences (GILD) NASH Expectations Were Low, RBC Says; PT Trimmed to $84

February 12, 2019 6:53 AM EST

RBC Capital analyst Brian Abrahams lowered the price target on Gilead Sciences (NASDAQ: GILD) to $84.00 (from $89.00) while maintaining a Outperform rating after the company announced its first ph.III study of selonsertib in NASH, STELLAR 4, failed.

"... we believe expectations were low... More

Gilead Sciences (GILD) Falls 4% After-Hours Following Failure of Cirrhosis Study

February 11, 2019 4:33 PM EST

Gilead Sciences (NASDAQ: GILD) Falls 4% After-Hours Following Failure of Cirrhosis Study

... More